Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396236 · ClinicalTrials.gov registry record · Phase 3
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
NCT04396236: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT04396236 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 851 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04396236, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
Study Summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Primary Outcome
Pain freedom at 2 hours post-dose was defined as having a pain intensity of none at that time point. Pain was measured on a 5-face pain scale, with following scores: 1= none, 2= mild, 3 and 4= moderate, 5= severe. Participants with a reduction in baseline pain as measured on a 5-Face Pain Scale from moderate (Faces 3 and 4) or severe (Face 5) to no pain (Face 1) were considered as pain freedom. 5-Face Pain Scale; minimum value: 1 (no pain); maximum value: 5 (severe pain); higher scores indicate
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 3 |
Why NCT04396236 stopped before completion
NCT04396236 is an interventional study that assigns participants to a tested intervention. The registered 851 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04396236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04396236 about?
NCT04396236 is a clinical study titled "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine". The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
What is the current status of trial NCT04396236?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2020-06-15. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT04396236?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT04396236?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04396236's enrollment target sits among peer trials
851 386th of 2000 higher than 1,614 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI